This site is intended for healthcare professionals
Abstract digital waveforms in blue and purple
FDA Drug information

Estradiol

Read time: 1 mins
Marketing start date: 28 Dec 2024
...
 

Summary of product characteristics


Effective Time

20221207

Version

1

Spl Product Data Elements

Estradiol Estradiol ESTRADIOL ESTRADIOL OLEIC ACID POVIDONE PROPYLENE GLYCOL SILICON DIOXIDE Estradiol Estradiol ESTRADIOL ESTRADIOL OLEIC ACID POVIDONE PROPYLENE GLYCOL SILICON DIOXIDE Estradiol Estradiol ESTRADIOL ESTRADIOL OLEIC ACID POVIDONE PROPYLENE GLYCOL SILICON DIOXIDE Estradiol Estradiol ESTRADIOL ESTRADIOL OLEIC ACID POVIDONE PROPYLENE GLYCOL SILICON DIOXIDE Estradiol Estradiol ESTRADIOL ESTRADIOL OLEIC ACID POVIDONE PROPYLENE GLYCOL SILICON DIOXIDE

Application Number

ANDA206241

Brand Name

Estradiol

Generic Name

Estradiol

Product Ndc

70771-1566

Product Type

HUMAN PRESCRIPTION DRUG

Route

TRANSDERMAL

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL Package Label – 0.025 mg NDC 70771-1563-8 Estradiol Transdermal System, USP (Twice-Weekly) Delivers 0.025 mg/day Includes 8 Systems Rx Only zydus pharmaceuticals 0.025mg

Drug section

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.